RecruitingNot ApplicableNCT06885671

Single vs Hypofractionated Irradiation For Timely Access to Partial Breast Radiotherapy

Phase II Single vs Hypofractionated Irradiation For Timely Access to Partial Breast Radiotherapy: SHIFT-PB


Sponsor

British Columbia Cancer Agency

Enrollment

60 participants

Start Date

Jun 8, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Partial Breast Irradiation (PBI) is a targeted radiation approach commonly administered post-lumpectomy, specifically targeting the tumour bed. This targeted therapy reduces the exposure to other nearby tissues such as lungs, heart, and chest wall. However, traditional PBI treatment involves lengthy multiple fraction courses which presents a burden to patients from rural and remote communities, who must travel long distances to receive high quality cancer care. The purpose of this study is to compare single fraction (SF) PBI vs. multiple fraction (MF) PBI.


Eligibility

Sex: FEMALEMin Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Multiple Fraction PBI and Single Fraction PBI for people with breast cancer early stage breast cancer (stage 1-3). The study is currently recruiting participants at 1 location. People eligible for this study include women aged 40 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONMultiple Fraction PBI

Participants randomized to Arm 1 will receive PBI with a dose of 26 Gy in 5 daily fractions.

RADIATIONSingle Fraction PBI

Participants randomized to Arm 2 will receive PBI in a single fraction with a dose of 13 Gy.


Locations(1)

BC Cancer - Prince George

Prince George, British Columbia, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06885671


Related Trials